Non-interventional Study Describing Patients' Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamin K Antagonist for Stroke Prophylaxis in Atrial Fibrillation.
Phase of Trial: Phase IV
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Atrial fibrillation; Stroke
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 01 Feb 2018 Status changed from active, no longer recruiting to completed.
- 28 Nov 2017 Planned End Date changed from 10 Dec 2017 to 29 Dec 2017.
- 28 Nov 2017 Planned primary completion date changed from 10 Dec 2017 to 29 Dec 2017.